Supernus Pharmaceuticals, Inc.
SUPNNASDAQHealthcare● Active
$44.48
$-0.27(-0.60%)
Market Cap$2.6B
P/E Ratio—
52W High$59.68
52W Low$30.83
Supernus Pharmaceuticals, Inc. (SUPN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SUPN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.59
Est. $0.28 · +110.7%
Revenue
$0.21B
Est. $0.19B · +7.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 8-Quarter EPS Beat Streak
SUPN reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.46 | — | — | — | $0.21B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.28 | $0.59 | +110.7% | $0.21B | $0.19B | +7.7% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $0.28 | $0.92 | +228.6% | $0.21B | $0.20B | +8.4% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.82 | $1.01 | +23.2% | $0.19B | $0.19B | -1.4% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $0.47 | $0.91 | +93.6% | $0.17B | $0.17B | -1.6% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.38 | $0.42 | +10.5% | $0.15B | $0.15B | +1.3% |
| ▲ Q1 FY2025 | Feb 25, 2025 | $0.46 | $0.75 | +63.0% | $0.17B | $0.16B | +12.2% |
| ▲ Q4 FY2024 | Nov 4, 2024 | $0.39 | $1.06 | +171.8% | $0.18B | $0.15B | +13.7% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.59
EPS Est.
$0.28
EPS Surpr.
+110.7%
Revenue
$0.21B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.92
EPS Est.
$0.28
EPS Surpr.
+228.6%
Revenue
$0.21B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$1.01
EPS Est.
$0.82
EPS Surpr.
+23.2%
Revenue
$0.19B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$0.91
EPS Est.
$0.47
EPS Surpr.
+93.6%
Revenue
$0.17B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.42
EPS Est.
$0.38
EPS Surpr.
+10.5%
Revenue
$0.15B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
$0.75
EPS Est.
$0.46
EPS Surpr.
+63.0%
Revenue
$0.17B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$1.06
EPS Est.
$0.39
EPS Surpr.
+171.8%
Revenue
$0.18B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.06 | $1.08 | $1.10 | 1 |
| Q3 FY2027 | $0.91 | $0.94 | $0.95 | 1 |
| Q2 FY2027 | $0.68 | $0.70 | $0.71 | 1 |
| Q1 FY2027 | $0.48 | $0.49 | $0.50 | 1 |
| Q4 FY2026 | $0.67 | $0.69 | $0.70 | 1 |
| Q3 FY2026 | $0.55 | $0.59 | $0.62 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.3B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +110.7% | $48.63 | $49.19 | +1.15% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +228.6% | $50.69 | $53.30 | +5.15% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +23.2% | $55.70 | $57.00 | +2.33% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +93.6% | $37.05 | $37.53 | +1.30% |
| ▲ Q2 FY2025 | May 6, 2025 | +10.5% | $32.39 | $32.43 | +0.12% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +63.0% | $32.68 | $32.81 | +0.40% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +171.8% | $33.97 | $34.70 | +2.15% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +16.1% | $27.92 | $27.88 | -0.14% |
Q2 FY2026+1.15%
Report Date
May 5, 2026
EPS Beat/Miss
+110.7%
Price Before
$48.63
Price After
$49.19
Q1 FY2026+5.15%
Report Date
Feb 24, 2026
EPS Beat/Miss
+228.6%
Price Before
$50.69
Price After
$53.30
Q4 FY2025+2.33%
Report Date
Nov 4, 2025
EPS Beat/Miss
+23.2%
Price Before
$55.70
Price After
$57.00
Q3 FY2025+1.30%
Report Date
Aug 5, 2025
EPS Beat/Miss
+93.6%
Price Before
$37.05
Price After
$37.53
Q2 FY2025+0.12%
Report Date
May 6, 2025
EPS Beat/Miss
+10.5%
Price Before
$32.39
Price After
$32.43
Q1 FY2025+0.40%
Report Date
Feb 25, 2025
EPS Beat/Miss
+63.0%
Price Before
$32.68
Price After
$32.81
Q4 FY2024+2.15%
Report Date
Nov 4, 2024
EPS Beat/Miss
+171.8%
Price Before
$33.97
Price After
$34.70
Q3 FY2024-0.14%
Report Date
Aug 6, 2024
EPS Beat/Miss
+16.1%
Price Before
$27.92
Price After
$27.88
Avg Beat Reaction+1.56%
Beat Rate8 / 8 quarters
Largest Move+5.15% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SUPN ends December
Supernus Pharmaceuticals, Inc. (SUPN) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.59 — beating the analyst consensus of $0.28 by +110.7%. SUPN has beaten EPS estimates for 8 consecutive quarters. The next SUPN earnings date is expected around September 1, 2026.
Each quarter, investors track SUPN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SUPN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SUPN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SUPN earnings · 5 questionsSupernus Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. SUPN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SUPN historically reports after market close (AMC).
SUPN earnings datewhen is SUPN earningsSUPN next earnings datewhen does SUPN report earningsSUPN earnings calendar
▸ Source: FMP · Supernus Pharmaceuticals, Inc. SEC filings · US GAAP · Supernus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026